[CAS NO. 1448671-31-5] AZD3965

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1448671-31-5]

Catalog

SLK-S7339

Brand

Selleck

CAS

1448671-31-5

DESCRIPTION [1448671-31-5]

Overview

MDL	MFCD28963899
Molecular Weight	515.51
Molecular Formula	C21H24F3N5O5S
SMILES	O=C1N(C(C)C)C2=C(C(C(N3OC[C@@](C)(O)C3)=O)=C(CC4=C(C)NN=C4C(F)(F)F)S2)C(N1C)=O

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	1.9398 mL	9.6991 mL	19.3983 mL
5 mM	0.3880 mL	1.9398 mL	3.8797 mL
10 mM	0.1940 mL	0.9699 mL	1.9398 mL
50 mM	0.0388 mL	0.1940 mL	0.3880 mL

Description

AZD3965 is a potent, selective and orally available monocarboxylate transporter 1 () inhibitor with a binding affinity of 1.6 nM, 6-fold selective over MCT2. Phase 1.

Targets

MCT1 ^[1]

In vitro

In lymphoma cell lines that preferentially express MCT1, AZD3965 potently inhibits lactate transport and cell growth. AZD3965 inhibits MCT1 activity in cells, and shows higher sensitivity in hypoxia. In H526, HGC27 cells and DMS114 cells, AZD3965 increases intracellular lactate and significantly reduces lactate uptake.

References

[1] Critchlow SE, et al. 2012. AACR 103rd Annual Meeting.
[2] Polański R, et al. Clin Cancer Res. 2014, 20(4), 926-937.
[3] Bola BM, et al. Mol Cancer Ther. 2014, 13(12), 2805-2816.